CO2023005372A2 - Composiciones de escherichia coli y métodos de las mismas - Google Patents

Composiciones de escherichia coli y métodos de las mismas

Info

Publication number
CO2023005372A2
CO2023005372A2 CONC2023/0005372A CO2023005372A CO2023005372A2 CO 2023005372 A2 CO2023005372 A2 CO 2023005372A2 CO 2023005372 A CO2023005372 A CO 2023005372A CO 2023005372 A2 CO2023005372 A2 CO 2023005372A2
Authority
CO
Colombia
Prior art keywords
methods
escherichia coli
compositions
coli compositions
coli
Prior art date
Application number
CONC2023/0005372A
Other languages
English (en)
Spanish (es)
Inventor
Annaliesa Sybil Anderson
Laurent Oliver Chorro
Rosalind Pan
Robert George Konrad Donald
Jacqueline Marie Lypowy
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CO2023005372A2 publication Critical patent/CO2023005372A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/26—Klebsiella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CONC2023/0005372A 2020-10-27 2023-04-27 Composiciones de escherichia coli y métodos de las mismas CO2023005372A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063106077P 2020-10-27 2020-10-27
US202163144058P 2021-02-01 2021-02-01
US202163254195P 2021-10-11 2021-10-11
PCT/IB2021/059820 WO2022090893A2 (en) 2020-10-27 2021-10-25 Escherichia coli compositions and methods thereof

Publications (1)

Publication Number Publication Date
CO2023005372A2 true CO2023005372A2 (es) 2023-05-19

Family

ID=78500672

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0005372A CO2023005372A2 (es) 2020-10-27 2023-04-27 Composiciones de escherichia coli y métodos de las mismas

Country Status (11)

Country Link
EP (1) EP4237428A2 (zh)
JP (1) JP2023546615A (zh)
KR (1) KR20230096033A (zh)
AU (1) AU2021368151A1 (zh)
CA (1) CA3199610A1 (zh)
CO (1) CO2023005372A2 (zh)
IL (1) IL302362A (zh)
MX (1) MX2023004912A (zh)
PE (1) PE20231934A1 (zh)
TW (1) TW202227467A (zh)
WO (1) WO2022090893A2 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023111907A1 (en) 2021-12-17 2023-06-22 Pfizer Inc. Polynucleotide compositions and uses thereof

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
AU651949B2 (en) 1989-07-14 1994-08-11 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
IL98715A0 (en) 1990-08-13 1992-07-15 American Cyanamid Co Filamentous hemaglutinin of bodetella pertussis as a carrier molecule for conjugate vaccines
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
DE69324487T2 (de) 1992-05-06 1999-08-12 Harvard College Rezeptorbindende region des diphtherietoxius
PL170980B1 (pl) 1992-06-25 1997-02-28 Smithkline Beecham Biolog Szczepionka PL PL PL PL PL PL PL
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
DE69434079T2 (de) 1993-03-05 2005-02-24 Wyeth Holdings Corp. Plasmid zur Herstellung von CRM-Protein und Diphtherie-Toxin
ES2162139T5 (es) 1993-03-23 2008-05-16 Smithkline Beecham Biologicals S.A. Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado.
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
US5846547A (en) 1996-01-22 1998-12-08 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
DE69838294T2 (de) 1997-05-20 2009-08-13 Ottawa Health Research Institute, Ottawa Verfahren zur Herstellung von Nukleinsäurekonstrukten
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
ES2298316T3 (es) 1997-09-05 2008-05-16 Glaxosmithkline Biologicals S.A. Emulsiones de aceite en agua que contienen saponinas.
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
ES2284247T3 (es) 1998-04-03 2007-11-01 University Of Iowa Research Foundation Metodos y productos para estimular el sistema inmunitario usando oligonucleotidos y citoquinas inmunoterapeuticos.
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
EP1126876B1 (en) 1998-10-16 2007-03-21 GlaxoSmithKline Biologicals S.A. Adjuvant systems and vaccines
WO2000037105A2 (en) 1998-12-21 2000-06-29 Medimmune, Inc. Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
ES2306528T3 (es) 1998-12-23 2008-11-01 Id Biomedical Corporation Antigenos de streptococcus.
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
AU783344B2 (en) 1999-02-17 2005-10-20 Csl Limited Immunogenic complexes and methods relating thereto
MY125202A (en) 1999-03-19 2006-07-31 Smithkline Beecham Biologicals S A Vaccine
JP2002541808A (ja) 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド ポリサッカリド結合体ワクチンのための組換えトキシンａタンパク質キャリア
DK1187629T3 (da) 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
EP1221971A2 (en) 1999-09-24 2002-07-17 SmithKline Beecham Biologics SA Use of the combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
CZ20021045A3 (cs) 1999-09-24 2002-08-14 Smithkline Beecham Biologicals S. A. Pomocný prostředek
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
CA2413450C (en) 2000-06-20 2014-02-18 Shire Biochem Inc. Streptococcus antigens
WO2002004496A2 (en) * 2000-07-07 2002-01-17 Medimmune, Inc. Fimh adhesin proteins and methods of use
US20030035806A1 (en) 2001-05-11 2003-02-20 D'ambra Anello J. Novel meningitis conjugate vaccine
AU2002351623A1 (en) 2001-12-20 2003-07-09 Shire Biochem Inc. Streptococcus antigens
BRPI0408094A (pt) 2003-03-13 2006-02-14 Glaxosmithkline Biolog Sa processo para purificação de uma citolisina bacteriana, citolisina bacteriana, conjugado de polissacarìdeo capsular-pneumolisina bacteriano, composição imunogênica, vacina, processo de produção da vacina, método de tratamento ou prevenção de infecção por streptococcus pneumoniae, e, uso da pneumolisina ou do conjugado de polissacarìdeo-pneumolisina bacteriano
WO2004083251A2 (en) 2003-03-17 2004-09-30 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
AU2005333126A1 (en) 2004-07-18 2006-12-21 Csl Limited Methods and compositions for inducing innate immune responses
JP2008506789A (ja) 2004-07-18 2008-03-06 シーエスエル、リミテッド インターフェロン−ガンマ応答強化を誘発するための免疫刺激複合体及びオリゴヌクレオチド処方物
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
IL308456A (en) 2005-04-08 2024-01-01 Wyeth Llc A multivalent pneumomuroral protein-polysaccharide conjugate preparation
BRPI0813644B8 (pt) 2007-06-26 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, processo para fabricar a mesma, e, uso da composição imunogênica ou vacina
BRPI1014494A2 (pt) 2009-04-30 2016-08-02 Coley Pharm Group Inc vacina pneumocócica e usos da mesma
IN2015DN00694A (zh) 2012-08-16 2015-06-26 Pfizer
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
EP3055416B1 (en) * 2013-10-11 2020-01-22 GlaxoSmithKline Biologicals S.A. Methods of host cell modification
EP3193918A4 (en) * 2014-09-18 2018-06-20 University of Maryland, Baltimore Broad spectrum conjugate vaccine to prevent klebsiella pneumoniae and pseudomonas aeruginosa infections
CN111372946A (zh) 2017-02-17 2020-07-03 隆萨有限公司 难以表达的蛋白质的多位点特异性整合细胞
GB201711635D0 (en) * 2017-07-19 2017-08-30 Glaxosmithkline Biologicals Sa Immunogenic composition
US11260119B2 (en) * 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
IL292494A (en) * 2019-11-01 2022-06-01 Pfizer Preparations of Escherichia coli and their methods
JP2023514697A (ja) * 2020-02-23 2023-04-07 ファイザー・インク 大腸菌組成物およびその方法

Also Published As

Publication number Publication date
AU2021368151A1 (en) 2023-06-01
AU2021368151A8 (en) 2023-06-22
KR20230096033A (ko) 2023-06-29
TW202227467A (zh) 2022-07-16
EP4237428A2 (en) 2023-09-06
IL302362A (en) 2023-06-01
PE20231934A1 (es) 2023-12-01
CA3199610A1 (en) 2022-05-05
WO2022090893A3 (en) 2022-06-09
JP2023546615A (ja) 2023-11-06
WO2022090893A2 (en) 2022-05-05
MX2023004912A (es) 2023-05-16

Similar Documents

Publication Publication Date Title
CO2021009695A2 (es) Conjugados de il-2 y métodos de uso de este
CO2023005372A2 (es) Composiciones de escherichia coli y métodos de las mismas
CL2021003191A1 (es) Inhibidores de tead y usos de los mismos
CL2021003190A1 (es) Inhibidores de tead y usos de los mismos
CO2020010303A2 (es) Conjugados de il-15, y sus usos
CO2022001210A2 (es) Conjugados de il-2 y métodos de uso para tratar enfermedades autoinmunes
MX2022005252A (es) Composiciones de escherichia coli y metodos de las mismas.
BR112021015477A2 (pt) Anticorpos anti-cd228 e conjugados anticorpo-fármaco
CO2022011991A2 (es) Composiciones de esquerichia coli y sus métodos
CL2018001941A1 (es) Anticuerpos anti tgfbeta 2
CO2022000029A2 (es) Preparados de prevotella y tratamiento de la enfermedad pulmonar obstructiva crónica (epoc) y otras afecciones pulmonares
CO2021010786A2 (es) Toxinas apxia, apxiia y apxiiia inactivadas
CO2021000147A2 (es) Composición agrícola
BR112022019412A2 (pt) Combinação herbicida
CO2023014770A2 (es) Degradadores de cdk2 y sus usos
BR112023001471A2 (pt) Composição farmacêutica de anticorpo anti-pd-1 e uso da mesma
EA202191403A1 (ru) Композиция с высокой концентрацией белка
EA202092335A1 (ru) Композиции на основе эренумаба и пути их применения
CL2022002571A1 (es) Agentes de fijación a tie2 y métodos de uso.
AR121394A1 (es) Composiciones de esquerichia coli y sus métodos
BR112022026670A2 (pt) Excipientes de redução da viscosidade e combinações dos mesmos para formulações de proteína altamente concentradas
BR112021017147A2 (pt) Proteínas de domínio ccn recombinantes e proteínas de fusão
CY1124122T1 (el) Απορροφησιμη βιοαποικοδομησιμη ιατρικη και καλλυντικη συνθεση
CO2020013557A2 (es) Variantes de lfa3 y composiciones y usos de las mismas
EA202192420A1 (ru) Применение онколитических вирусов для лечения рака